Marinomed Biotechnologie GmbH
Mag. Johanna Uhlmann
Veterinärplatz 1
Vienna
1210
Tel: 43-1-25077-4460
Fax: 43-1-25077-4493
Website: http://www.marinomed.com/
Email: office@marinomed.com
About Marinomed Biotechnologie GmbH
Marinomed Biotech AG is a biopharmaceutical company based in Vienna. The company’s already marketed products are used in the treatment of colds and flu-like infections based on the MAVIREX® platform. The products are sold through international partners in more than 35 countries throughout the world. The company has developed additional products for use in the treatment of allergies and autoimmune diseases based on the patent-pending MARINOSOLV® platform. Marinomed Biotechnologie GmbH was founded in 2006 as a spin-off of the University of Veterinary Medicine, Vienna.YEAR FOUNDED:
2006
LEADERSHIP:
CEO: Andreas Grassauer
CSO: Eva Prieschl-Grassauer
CFO: Helmut Baranyovszki
JOBS:
Please click here for Marinomed Biotech job opportunities.
19 articles about Marinomed Biotechnologie GmbH
-
Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray
10/21/2021
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd., signed a licensing agreement with Austria-based Marinomed Biotech AG, whereby Shandong Luoxin will gain the exclusive rights for the development, manufacture, and commercialization of Budesolv® in China.
-
Marinomed Extends The Range of Marinosolv® Applications
3/9/2020
Marinomed Biotech AG, a globally active biopharmaceutical company based in Vienna, has achieved promising results for further areas of application with its Marinosolv® technology platform in preclinical studies.
-
Marinosolv® technology successfully used in preclinical study in severe eye disease Neurotrophic keratopathy
2/6/2020
Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, and the renowned University of Utah have published scientific investigations that provide initial evidence for further significant benefits of the innovative Marinosolv® platform in the field of corneal eye diseases.
-
Marinomed Biotech AG: Detailed Clinical Data Show Rapid Onset of Action of Budesolv to Alleviate Hay Fever
11/26/2019
Marinomed Biotech AG has presented detailed data from its pivotal Phase III clinical trial for the therapeutic comparability of an aqueous solution of budesonide, a synthetic steroid for the treatment of hay fever.
-
VIENNA-BASED BIOTECH COMPANY MARINOMED ON A GROWTH PATH
8/29/2018
Vienna-based Marinomed Biotech AG (Marinomed) continues its growth path. The company is making significant progress in developing its Marinosolv® technology platform and can start a Phase III clinical approval study for the first product derived from the technology platform earlier than expected, still in winter 2018/19.
-
VIENNA-BASED BIOTECH COMPANY MARINOMED OBTAINS EU-WIDE CERTIFICATION FOR NEW COLD MEDICATION
8/7/2018
Vienna-based company Marinomed Biotech AG (Marinomed) today announced it had secured EU-wide certification for a new product: a nasal spray that allows the decongestion of the nasal cavity without employing a pharmaceutical ingredient and tackles viral infections of the airways at the same time.
-
Marinomed Biotech Raises 7 Million Euros On Capital Market
7/20/2017
-
Marinomed Biotechnologie GmbH: New Investment Boosts Global Expansion & Innovation
10/6/2015
-
Effectiveness Of Marinomed Biotechnologie GmbH's Antiviral Nasal Spray Confirmed In Clinical Trial For Common Cold
12/5/2013
-
Marinomed Biotechnologie GmbH has Licensed the Rights of 5 Drugs for the Chinese Market
7/17/2013
-
Marinomed Biotechnologie GmbH Release: Antiviral Nasal Spray - Data From Two Clinical Studies Prove Effectiveness of Marinomed's Antiviral Drug
3/15/2013
-
Marinomed Biotechnologie GmbH's Antiviral Spray Fights Cold in Canada
3/5/2013
-
Marinomed Biotechnologie GmbH Granted Chinese Patent for Antiviral Polymer
11/19/2012
-
Marinomed Biotechnologie GmbH Appoints Head of Development
10/27/2011
-
Marinomed Biotechnologie GmbH's Iota-Carrageenan Effective Against H1N1
12/15/2010
-
Marinomed Biotechnologie GmbH’s Antiviral Effective in Clinical Trial for Common Cold
8/11/2010
-
Marinomed Biotechnologie GmbH Signs Collaboration with Boehringer Ingelheim Corporation for Anti-Viral Nasal Spray Against Common Cold
6/28/2010
-
Marinomed Biotechnologie GmbH's MAM-06.301 Achieves Preclinical POC
5/25/2010
-
Marinomed Biotechnologie GmbH Granted European Patent for Anti-Viral Active Ingredient
3/12/2010